Virus-like particle
Virus-like particle (VLP) refers to a molecular structure that closely resembles a virus but is non-infectious because it lacks the viral genome. VLPs are composed of viral proteins that can self-assemble into structures mimicking the virus's outer shell or capsid. These particles are significant in biotechnology, vaccine development, and nanotechnology.
Structure and Assembly[edit]
VLPs are formed from the self-assembly of one or more structural proteins derived from the virus. These proteins can form capsids or envelopes similar to those of the native virus. The assembly process can occur in various expression systems, including bacteria, yeast, insect cells, and mammalian cells.
Applications[edit]
Vaccines[edit]
VLPs are widely used in the development of vaccines because they can elicit strong immune responses without the risk of infection. Notable examples include the Hepatitis B vaccine and the HPV vaccine. These vaccines use VLPs to present viral antigens to the immune system, prompting the production of antibodies.
Gene Therapy[edit]
In gene therapy, VLPs can be used as delivery vehicles for gene editing tools or therapeutic genes. Their ability to mimic the structure of viruses allows them to efficiently enter cells and deliver their payload.
Nanotechnology[edit]
VLPs are also explored in nanotechnology for their potential to serve as nanocarriers for drug delivery, imaging agents, and other therapeutic applications. Their uniform size and ability to be modified make them ideal candidates for these purposes.
Production[edit]
The production of VLPs involves the expression of viral structural proteins in a suitable host system. Commonly used systems include:
Each system has its advantages and limitations regarding yield, post-translational modifications, and scalability.
Advantages[edit]
- **Safety**: VLPs are non-infectious as they lack the viral genome.
- **Immunogenicity**: They can induce strong immune responses.
- **Versatility**: VLPs can be engineered to display various antigens or therapeutic molecules.
Challenges[edit]
- **Production Costs**: High production costs can be a barrier.
- **Stability**: Ensuring the stability of VLPs during storage and transport can be challenging.
- **Scalability**: Scaling up production while maintaining quality and consistency is complex.
Examples of VLP-based Vaccines[edit]
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
